How many Pfizer-related Phantom Stock Units does Albert Bourla hold after this grant?

After this grant of 22 Phantom Stock Units, Albert Bourla holds 760,229 units in total. This figure reflects his direct holdings of phantom units under Pfizer’s deferred compensation plan following the April 30, 2026 transaction reported in the Form 4 filing.

Pfizer (PFE) CEO Bourla awarded 22 cash-settled phantom stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 22 Phantom Stock Units linked to Pfizer common stock on April 30, 2026. Each unit represents one phantom share of common stock and is part of a deferred compensation arrangement, not an open-market stock purchase.

The units were awarded under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan and will be settled in cash after his separation from service. Following this grant, Bourla holds a total of 760,229 Phantom Stock Units directly under this plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BOURLA ALBERT

Role Chairman & CEO

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units SSP	22	$26.70	$587.40

Holdings After Transaction: Phantom Stock Units SSP — 760,229 shares (Direct, null)

Footnotes (1)

Each unit represents one phantom share of common stock. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Key Figures

Phantom Stock Units granted: 22 units Grant reference price: $26.70 per unit Total phantom units after grant: 760,229 units +2 more

5 metrics

Phantom Stock Units granted 22 units Grant on April 30, 2026 as compensation award

Grant reference price $26.70 per unit Price per unit used for the April 30, 2026 award

Total phantom units after grant 760,229 units Albert Bourla’s holdings in Phantom Stock Units following the transaction

Underlying security shares 22 shares Each Phantom Stock Unit corresponds to one share of Pfizer common stock in value

Conversion or exercise price $0.00 Phantom Stock Units have no exercise price and are cash-settled

Key Terms

Phantom Stock Units, Nonfunded Deferred Compensation and Supplemental Savings Plan, settled in cash, grant/award acquisition

4 terms

Phantom Stock Units financial

"Each unit represents one phantom share of common stock."

Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.

Nonfunded Deferred Compensation and Supplemental Savings Plan financial

"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash"

settled in cash financial

"are settled in cash following the reporting person's separation from service"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 04:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOURLA ALBERT

(Last)

(First)

(Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK

10001-2192

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock Units SSP	⁽¹⁾	04/30/2026		A		22		⁽²⁾	⁽²⁾	Common Stock	22	$26.7	760,229	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

	/s/ Shanice A. Reid, by power of atty., for Albert Bourla	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pfizer (PFE) CEO Albert Bourla report in this Form 4 filing?

Albert Bourla reported receiving 22 Phantom Stock Units tied to Pfizer common stock. These units are a deferred compensation award, not a market stock purchase, and increase his total phantom unit holdings under the plan to 760,229 units following the transaction.

Are the securities in Albert Bourla’s Pfizer (PFE) Form 4 actual shares?

No, the Form 4 reports Phantom Stock Units, not actual Pfizer shares. Each unit tracks one share of common stock in value, but the award is settled in cash under a deferred compensation plan rather than through delivery of Pfizer stock.

How and when are Albert Bourla’s Pfizer Phantom Stock Units settled?

The Phantom Stock Units are settled in cash after Albert Bourla’s separation from service. Under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan, these units mirror Pfizer’s stock value and may be transferred into an alternative investment account by him at any time.

Does this Pfizer (PFE) Form 4 show any stock being bought or sold on the market?

No, the filing shows a grant of Phantom Stock Units as compensation, not market trades. The transaction is coded as an acquisition (grant or award) and involves cash-settled phantom units under a deferred compensation plan rather than open-market buying or selling of Pfizer shares.